Daunorubicin/cytarabine explained

Type:combo
Component1:Daunorubicin
Class1:Anthracycline
Component2:Cytarabine
Class2:Antimetabolite
Tradename:Vyxeos
Dailymedid:Vyxeos
Pregnancy Au:D
Routes Of Administration:Intravenous
Atc Prefix:L01
Atc Suffix:XY01
Legal Au:S4
Legal Au Comment:[1]
Legal Ca:Rx-only
Legal Ca Comment:[2]
Legal Us:Rx-only
Legal Us Comment:[3]
Legal Eu:Rx-only
Legal Eu Comment:[4]
Cas Number:1256639-86-7
Kegg:D11390
Synonyms:CPX-351

Daunorubicin/cytarabine, sold under the brand name Vyxeos, is a fixed-dose combination medication used for the treatment of acute myeloid leukemia.[5] It contains the liposomal bound daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.

Medical uses

Daunorubicin/cytarabine is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in people aged one year of age and older.[6] [7] [8] [9]

Notes and References

  1. Web site: Vyxeos APMDS . Therapeutic Goods Administration (TGA) . 15 June 2022 . 18 June 2022 . 18 June 2022 . https://web.archive.org/web/20220618050917/https://www.tga.gov.au/apm-summary/vyxeos . live .
  2. Web site: Health product highlights 2021: Annexes of products approved in 2021 . . 3 August 2022 . 25 March 2024.
  3. Web site: Vyxeos (- daunorubicin and cytarabine liposome injection, powder, lyophilized, for suspension . DailyMed . 13 April 2021 . 18 June 2022 . 29 March 2021 . https://web.archive.org/web/20210329140335/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea701ce-e7d3-4349-a9c2-642a501d45c8 . live .
  4. Web site: Vyxeos liposomal EPAR . European Medicines Agency (EMA) . 23 August 2018 . 25 May 2024.
  5. Molica M, Perrone S, Mazzone C, Cesini L, Canichella M, de Fabritiis P . CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML . Cancers . 14 . 12 . 2843 . June 2022 . 35740508 . 9221356 . 10.3390/cancers14122843 . free .
  6. Web site: Vyxeos (cytarabine/daunorubicin liposomal) dosing, indications, interactions, adverse effects, and more. Medscape. 19 March 2019. 15 August 2017. https://web.archive.org/web/20170815130425/http://reference.medscape.com/drug/vyxeos-cytarabine-daunorubicin-liposomal-1000185. live.
  7. Web site: Vyxeos (cytarabine and daunorubicin) FDA Approval History. Drugs.com. 30 December 2018. 11 April 2019. https://web.archive.org/web/20190411070044/https://www.drugs.com/history/vyxeos.html. live.
  8. Chen EC, Fathi AT, Brunner AM . Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML . OncoTargets and Therapy . 11 . 3425–3434 . 2018 . 29928134 . 6003284 . 10.2147/OTT.S141212 . free .
  9. Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rorà A, Simonetti G, Martinelli G, Cerchione C . CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia . Minerva Medica . 111 . 5 . 455–466 . October 2020 . 32955826 . 10.23736/S0026-4806.20.07017-2 . 221842680 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Daunorubicin/cytarabine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.